Single-Dose Safety and Pharmacokinetics of ST-246, a Novel Orthopoxvirus Egress Inhibitor

ST-246 is a novel, potent orthopoxvirus egress inhibitor that is being developed to treat pathogenic orthopoxvirus infections of humans. This phase I, double-blind, randomized, placebo-controlled single ascending dose study (first time with humans) was conducted to determine the safety, tolerability...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Jordan, Robert, Tien, Deborah, Bolken, Tove' C., Jones, Kevin F., Tyavanagimatt, Shanthakumar R., Strasser, Josef, Frimm, Annie, Corrado, Michael L., Strome, Phoebe G., Hruby, Dennis E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology (ASM) 2008
Soggetti:
Antiviral Agents
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2346641/
https://ncbi.nlm.nih.gov/pubmed/18316519
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01303-07
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi